Literature DB >> 12531644

B- and T-cell responses to the mycobacterium surface antigen PstS-1 in the respiratory tract and adjacent tissues. Role of adjuvants and routes of immunization.

Ariane Rodríguez1, Marita Troye-Blomberg, Karin Lindroth, Juraj Ivanyi, Mahavir Singh, Carmen Fernández.   

Abstract

Induction of mucosal immunity in the respiratory tract is crucial for protection against respiratory infections. Here, we have investigated the effects of the routes of immunization as well as of three different adjuvants on the induction of mucosal immune responses. Mice were immunized using intranasal (i.n.) or intraperitoneal (i.p.) routes with the mycobacterium PstS-1 antigen. Cholera toxin (CT), detoxified pertussis toxin (detPT) and RU 41.740 from Klebsiella pneumoniae were compared as mucosal adjuvants. Our data showed that i.n. route of immunization induced the most favorable stimulation of mucosal antigen-specific IgA responses supported by mixed Th cells producing IL-4, IL-5, IFN-gamma. In contrast, i.p. immunizations elicited only enhancement of systemic responses, predominantly of the Th2 type. Furthermore, the use of CT as mucosal adjuvant resulted in the stimulation of a mixed Th cell response whereas detPT evoked mainly Th2 type of responses. Likewise CT, the RU 41.740 adjuvant elicited a mixed Th cell response, albeit supported by much lower numbers of CD4(+) T-cells. Thus, i.n. route of immunization favors the induction of mucosal and systemic immune responses, while the Th cell development at mucosal inductive site is influenced by the adjuvant used for immunizations.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12531644     DOI: 10.1016/s0264-410x(02)00478-4

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  6 in total

1.  Induction of mucosal immunity through systemic immunization: Phantom or reality?

Authors:  Fei Su; Girishchandra B Patel; Songhua Hu; Wangxue Chen
Journal:  Hum Vaccin Immunother       Date:  2016-01-11       Impact factor: 3.452

2.  Influence of maternal gestational treatment with mycobacterial antigens on postnatal immunity in an experimental murine model.

Authors:  Muhammad Jubayer Rahman; Irene Roman Dégano; Mahavir Singh; Carmen Fernández
Journal:  PLoS One       Date:  2010-03-15       Impact factor: 3.240

3.  Passive protection with immunoglobulin A antibodies against tuberculous early infection of the lungs.

Authors:  Ann Williams; Rajko Reljic; Irene Naylor; Simon O Clark; Gustavo Falero-Diaz; Mahavir Singh; Stephen Challacombe; Philip D Marsh; Juraj Ivanyi
Journal:  Immunology       Date:  2004-03       Impact factor: 7.397

4.  Intranasal bacille Calmette-Guerin (BCG) vaccine dosage needs balancing between protection and lung pathology.

Authors:  J A Tree; A Williams; S Clark; G Hall; P D Marsh; J Ivanyi
Journal:  Clin Exp Immunol       Date:  2004-12       Impact factor: 4.330

5.  Changes in the Immune Phenotype and Gene Expression Profile Driven by a Novel Tuberculosis Nanovaccine: Short and Long-Term Post-immunization.

Authors:  Amparo Martínez-Pérez; Ana Igea; Olivia Estévez; Catarina M Ferreira; Egídio Torrado; António Gil Castro; Carmen Fernández; Anna-Lena Spetz; Lucille Adam; Moisés López González; Mahavir Singh; Rajko Reljic; África González-Fernández
Journal:  Front Immunol       Date:  2021-01-28       Impact factor: 7.561

6.  Anti-epidermal growth factor receptor (EGFR) antibodies overcome resistance of ovarian cancer cells to targeted therapy and natural cytotoxicity.

Authors:  Nina Gottschalk; Rainer Kimmig; Stephan Lang; Mahavir Singh; Sven Brandau
Journal:  Int J Mol Sci       Date:  2012-09-20       Impact factor: 6.208

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.